<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD01690000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P08514</UniProt_ID>
  <Seq_Length>1039</Seq_Length>
  <Molecule_Weight>113377</Molecule_Weight>
  <KEGG_ID>hsa:3674</KEGG_ID>
  <Orthology_ID>K06476</Orthology_ID>
  <EBI_ID>EBI-702693</EBI_ID>
  <Function_Summary>Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It recognizes the sequence R-G-D in a wide array of ligands. It recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial cell surface.</Function_Summary>
  <Pfam_ID>PF01839:FG-GAP@@PF00357:Integrin_alpha@@PF08441:Integrin_alpha2</Pfam_ID>
  <Allosteric_Activator_Count>2</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>GPalpha IIb</Alias>
      <Alias>Platelet membrane glycoprotein IIb</Alias>
      <Alias>CD41</Alias>
      <Alias>GPIIb</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an identical protein or proteins.</Detail>
      <Keyword>Identical protein binding</Keyword>
      <Ontology_ID>GO:0042802</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>176</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>968</Position>
      <Original>Tyr</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>267</Position>
      <Original>Gly</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>1026</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>313</Position>
      <Original>Gly</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>752</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>273</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>86</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>581</Position>
      <Original>Ala</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>207</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>449</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>649</Position>
      <Original>Val</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>847</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>755</Position>
      <Original>Arg</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>778</Position>
      <Original>Gln</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>380</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>174</Position>
      <Original>Tyr</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>705</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>874</Position>
      <Original>Ile</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>40</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>355</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>412</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>989</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>176</Position>
      <Original>Pro</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>202</Position>
      <Original>Phe</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>596</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>320</Position>
      <Original>Phe</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>222</Position>
      <Original>Phe</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>358</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>943</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>982</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>405</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>214</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>329</Position>
      <Original>Val</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>139</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>161</Position>
      <Original>Cys</Original>
      <Variation>Trp</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The regulated exocytosis of secretory granules containing preformed mediators such as histamine and serotonin by a platelet.</Detail>
      <Keyword>Platelet degranulation</Keyword>
      <Ontology_ID>GO:0002576</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemotaxis process that directs the migration of an axon growth cone to a specific target site in response to a combination of attractive and repulsive cues.</Detail>
      <Keyword>Axon guidance</Keyword>
      <Ontology_ID>GO:0007411</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of an integrin binding to one of its physiological ligands.</Detail>
      <Keyword>Integrin-mediated signaling pathway</Keyword>
      <Ontology_ID>GO:0007229</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules.</Detail>
      <Keyword>Cell adhesion</Keyword>
      <Ontology_ID>GO:0007155</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.</Detail>
      <Keyword>Platelet activation</Keyword>
      <Ontology_ID>GO:0030168</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>891</Position>
      <PTM_Type>Pyrrolidone carboxylic acid</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE</Protein_Seq>
    <DNA_Seq>GATGGCCAGAGCTTTGTGTCCACTGCAAGCCCTCTGGCTTCTGGAGTGGGTGCTGCTGCTCTTGGGACCTTGTGCTGCCCCTCCAGCCTGGGCCTTGAACCTGGACCCAGTGCAGCTCACCTTCTATGCAGGCCCCAATGGCAGCCAGTTTGGATTTTCACTGGACTTCCACAAGGACAGCCATGGGAGAGTGGCCATCGTGGTGGGCGCCCCGCGGACCCTGGGCCCCAGCCAGGAGGAGACGGGCGGCGTGTTCCTGTGCCCCTGGAGGGCCGAGGGCGGCCAGTGCCCCTCGCTGCTCTTTGACCTCCGTGATGAGACCCGAAATGTAGGCTCCCAAACTTTACAAACCTTCAAGGCCCGCCAAGGACTGGGGGCGTCGGTCGTCAGCTGGAGCGACGTCATTGTGGCCTGCGCCCCCTGGCAGCACTGGAACGTCCTAGAAAAGACTGAGGAGGCTGAGAAGACGCCCGTAGGTAGCTGCTTTTTGGCTCAGCCAGAGAGCGGCCGCCGCGCCGAGTACTCCCCCTGTCGCGGGAACACCCTGAGCCGCATTTACGTGGAAAATGATTTTAGCTGGGACAAGCGTTACTGTGAAGCGGGCTTCAGCTCCGTGGTCACTCAGGCCGGAGAGCTGGTGCTTGGGGCTCCTGGCGGCTATTATTTCTTAGGTCTCCTGGCCCAGGCTCCAGTTGCGGATATTTTCTCGAGTTACCGCCCAGGCATCCTTTTGTGGCACGTGTCCTCCCAGAGCCTCTCCTTTGACTCCAGCAACCCAGAGTACTTCGACGGCTACTGGGGGTACTCGGTGGCCGTGGGCGAGTTCGACGGGGATCTCAACACTACAGAATATGTCGTCGGTGCCCCCACTTGGAGCTGGACCCTGGGAGCGGTGGAAATTTTGGATTCCTACTACCAGAGGCTGCATCGGCTGCGCGCAGAGCAGATGGCGTCGTATTTTGGGCATTCAGTGGCTGTCACTGACGTCAACGGGGATGGGAGGCATGATCTGCTGGTGGGCGCTCCACTGTATATGGAGAGCCGGGCAGACCGAAAACTGGCCGAAGTGGGGCGTGTGTATTTGTTCCTGCAGCCGCGAGGCCCCCACGCGCTGGGTGCCCCCAGCCTCCTGCTGACTGGCACACAGCTCTATGGGCGATTCGGCTCTGCCATCGCACCCCTGGGCGACCTCGACCGGGATGGCTACAATGACATTGCAGTGGCTGCCCCCTACGGGGGTCCCAGTGGCCGGGGCCAAGTGCTGGTGTTCCTGGGTCAGAGTGAGGGGCTGAGGTCACGTCCCTCCCAGGTCCTGGACAGCCCCTTCCCCACAGGCTCTGCCTTTGGCTTCTCCCTTCGAGGTGCCGTAGACATCGATGACAACGGATACCCAGACCTGATCGTGGGAGCTTACGGGGCCAACCAGGTGGCTGTGTACAGAGCTCAGCCAGTGGTGAAGGCCTCTGTCCAGCTACTGGTGCAAGATTCACTGAATCCTGCTGTGAAGAGCTGTGTCCTACCTCAGACCAAGACACCCGTGAGCTGCTTCAACATCCAGATGTGTGTTGGAGCCACTGGGCACAACATTCCTCAGAAGCTATCCCTAAATGCCGAGCTGCAGCTGGACCGGCAGAAGCCCCGCCAGGGCCGGCGGGTGCTGCTGCTGGGCTCTCAACAGGCAGGCACCACCCTGAACCTGGATCTGGGCGGAAAGCACAGCCCCATCTGCCACACCACCATGGCCTTCCTTCGAGATGAGGCAGACTTCCGGGACAAGCTGAGCCCCATTGTGCTCAGCCTCAATGTGTCCCTACCGCCCACGGAGGCTGGAATGGCCCCTGCTGTCGTGCTGCATGGAGACACCCATGTGCAGGAGCAGACACGAATCGTCCTGGACTCTGGGGAAGATGACGTATGTGTGCCCCAGCTTCAGCTCACTGCCAGCGTGACGGGCTCCCCGCTCCTAGTTGGGGCAGATAATGTCCTGGAGCTGCAGATGGACGCAGCCAACGAGGGCGAGGGGGCCTATGAAGCAGAGCTGGCCGTGCACCTGCCCCAGGGCGCCCACTACATGCGGGCCCTAAGCAATGTCGAGGGCTTTGAGAGACTCATCTGTAATCAGAAGAAGGAGAATGAGACCAGGGTGGTGCTGTGTGAGCTGGGCAACCCCATGAAGAAGAACGCCCAGATAGGAATCGCGATGTTGGTGAGCGTGGGGAATCTGGAAGAGGCTGGGGAGTCTGTGTCCTTCCAGCTGCAGATACGGAGCAAGAACAGCCAGAATCCAAACAGCAAGATTGTGCTGCTGGACGTGCCGGTCCGGGCAGAGGCCCAAGTGGAGCTGCGAGGGAACTCCTTTCCAGCCTCCCTGGTGGTGGCAGCAGAAGAAGGTGAGAGGGAGCAGAACAGCTTGGACAGCTGGGGACCCAAAGTGGAGCACACCTATGAGCTCCACAACAATGGCCCTGGGACTGTGAATGGTCTTCACCTCAGCATCCACCTTCCGGGACAGTCCCAGCCCTCCGACCTGCTCTACATCCTGGATATACAGCCCCAGGGGGGCCTTCAGTGCTTCCCACAGCCTCCTGTCAACCCTCTCAAGGTGGACTGGGGGCTGCCCATCCCCAGCCCCTCCCCCATTCACCCGGCCCATCACAAGCGGGATCGCAGACAGATCTTCCTGCCAGAGCCCGAGCAGCCCTCGAGGCTTCAGGATCCAGTTCTCGTAAGCTGCGACTCGGCGCCCTGTACTGTGGTGCAGTGTGACCTGCAGGAGATGGCGCGCGGGCAGCGGGCCATGGTCACGGTGCTGGCCTTCCTGTGGCTGCCCAGCCTCTACCAGAGGCCTCTGGATCAGTTTGTGCTGCAGTCGCACGCATGGTTCAACGTGTCCTCCCTCCCCTATGCGGTGCCCCCGCTCAGCCTGCCCCGAGGGGAAGCTCAGGTGTGGACACAGCTGCTCCGGGCCTTGGAGGAGAGGGCCATTCCAATCTGGTGGGTGCTGGTGGGTGTGCTGGGTGGCCTGCTGCTGCTCACCATCCTGGTCCTGGCCATGTGGAAGGTCGGCTTCTTCAAGCGGAACCGGCCACCCCTGGAAGAAGATGATGAAGAGGGGGAGTGATGGTGCAGCCTACACTATTCTAGCAGGAGGGTTGGGCGTGCTACCTGCACCGCCCCTTCTCCAACAAGTTGCCTCCAAGCTTTGGGTTGGAGCTGTTCCATTGGGTCCTCTTGGTGTCGTTTCCCTCCCAACAGAGCTGGGCTACCCCCCCTCCTGCTGCCTAATAAAGAGACTGAGCCCTG</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Prostate adenocarcinoma</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Platelets</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Megakaryocytes</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Melanoma cells</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Leukemia</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>ITGA2B</Gene_Name>
    <Gene_Alias>GP2B; ITGAB</Gene_Alias>
    <Gene_ID>3674</Gene_ID>
    <Genbank_ACCN>NM_000419</Genbank_ACCN>
    <Protein_ACCN>NP_000410</Protein_ACCN>
    <HGNC_ID>6138</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/3674</Gene_URL>
    <UCSC_ID>uc002igt.1</UCSC_ID>
    <EMBL_ID>ENSG00000005961</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P05106</Uniprot_ID>
      <Gene_Name>ITGB3</Gene_Name>
      <EBI_ID>EBI-702847</EBI_ID>
      <PPI_EBI_URL>EBI-702693,EBI-702847</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P08514</Uniprot_ID>
      <Gene_Name>ITGA2B</Gene_Name>
      <EBI_ID>EBI-702693</EBI_ID>
      <PPI_EBI_URL>EBI-702693,EBI-702693</PPI_EBI_URL>
      <Experiment_Number>7</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Thrombocytopenia</Disease_Name>
      <Disease_Detail>Thrombocytopenia</Disease_Detail>
      <Disease_DB>THR014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thrombocytopenia?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glanzmann's Thrombasthenia</Disease_Name>
      <Disease_Detail>Glanzmann's Thrombasthenia</Disease_Detail>
      <Disease_DB>GLN003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glanzmanns_thrombasthenia?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thrombasthenia of Glanzmann and Naegeli, Itga2b-Related</Disease_Name>
      <Disease_Detail>Thrombasthenia</Disease_Detail>
      <Disease_DB>THR046</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thrombasthenia_of_glanzmann_and_naegeli_itga2b_related?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemorrhagic Fever with Renal Syndrome</Disease_Name>
      <Disease_Detail>Hemorrhagic Fever</Disease_Detail>
      <Disease_DB>HMR004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemorrhagic_fever_with_renal_syndrome?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fetal and Neonatal Alloimmune Thrombocytopenia</Disease_Name>
      <Disease_Detail>Fetal and Neonatal Alloimmune Thrombocytopenia</Disease_Detail>
      <Disease_DB>FTL012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fetal_and_neonatal_alloimmune_thrombocytopenia?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myocardial Infarction</Disease_Name>
      <Disease_Detail>Myocardial Infarction</Disease_Detail>
      <Disease_DB>MYC007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myocardial_infarction?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myelitis</Disease_Name>
      <Disease_Detail>Myelitis</Disease_Detail>
      <Disease_DB>MYL001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myelitis?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Autoimmune Thrombocytopenic Purpura</Disease_Name>
      <Disease_Detail>Autoimmune Thrombocytopenic Purpura</Disease_Detail>
      <Disease_DB>ATM004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/autoimmune_thrombocytopenic_purpura?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Bleeding Disorder, Platelet-Type, 16, Autosomal Dominant</Disease_Name>
      <Disease_Detail>Bleeding Disorder, Platelet-Type, 16, Autosomal Dominant</Disease_Detail>
      <Disease_DB>BLD122</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bleeding_disorder_platelet_type_16_autosomal_dominant?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Purpura</Disease_Name>
      <Disease_Detail>Purpura</Disease_Detail>
      <Disease_DB>PRP030</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/purpura?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thrombocytopenia, Neonatal Alloimmune, Bak Antigen Related</Disease_Name>
      <Disease_Detail>Thrombocytopenia</Disease_Detail>
      <Disease_DB>THR094</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thrombocytopenia_neonatal_alloimmune_bak_antigen_related?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Megakaryocytic Leukemia</Disease_Name>
      <Disease_Detail>Megakaryocytic Leukemia</Disease_Detail>
      <Disease_DB>MGK001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/megakaryocytic_leukemia?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Arteriovenous Fistula</Disease_Name>
      <Disease_Detail>Arteriovenous Fistula</Disease_Detail>
      <Disease_DB>ART084</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/arteriovenous_fistula?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Bernard-Soulier Syndrome</Disease_Name>
      <Disease_Detail>Bernard-Soulier Syndrome</Disease_Detail>
      <Disease_DB>BRN019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bernard_soulier_syndrome?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Intermediate Coronary Syndrome</Disease_Name>
      <Disease_Detail>Intermediate Coronary Syndrome</Disease_Detail>
      <Disease_DB>INT007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/intermediate_coronary_syndrome?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thrombasthenia</Disease_Name>
      <Disease_Detail>Thrombasthenia</Disease_Detail>
      <Disease_DB>THR035</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thrombasthenia?search=ITGA2B#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Platelet integrin alfaIIb-beta3 cytoplasmic domain</PDB_Title>
      <PDB_ID>1M8O</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1M8O</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A structural mechanism of integrin alpha(IIb)beta(3) &quot;inside-out&quot; activation as regulated by its cytoplasmic face</PubMed_Title>
      <Author>Vinogradova O</Author>
      <Journal>Cell. 2002 Sep 6;110(5):587-97</Journal>
      <PubMed_ID>12230976</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Integrin alphaIIb-beta3 transmembrane complex</PDB_Title>
      <PDB_ID>2K9J</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2K9J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of the integrin alphaIIbbeta3 transmembrane complex explains integrin transmembrane signalling</PubMed_Title>
      <Author>Lau TL</Author>
      <Journal>EMBO J. 2009 May 6;28(9):1351-61</Journal>
      <PubMed_ID>19279667</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO A CHIMERIC FIBRINOGEN GAMMA CHAIN PEPTIDE, LGGAKQRGDV</PDB_Title>
      <PDB_ID>2VDR</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta3</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of complete ectodomain of integrin aIIBb3</PDB_Title>
      <PDB_ID>3FCS</PDB_ID>
      <Resolution>2.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3FCS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces</PubMed_Title>
      <Author>Zhu J</Author>
      <Journal>Mol Cell. 2008 Dec 26;32(6):849-61</Journal>
      <PubMed_ID>19111664</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO A CHIMERIC FIBRINOGEN GAMMA CHAIN PEPTIDE, HHLGGAKQRGDV</PDB_Title>
      <PDB_ID>2VDQ</PDB_ID>
      <Resolution>2.59</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta10</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Platelet integrin ALFAIIB-BETA3 transmembrane-cytoplasmic heterocomplex</PDB_Title>
      <PDB_ID>2KNC</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2KNC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A structure of integrin AlphaIIb beta3 transmembrane-cytoplasmic heterocomplex: new insight on the mechanism of integrin activation</PubMed_Title>
      <Author>Yang J</Author>
      <Journal>To be published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution Structure of the Membrane Proximal Regions of alpha-IIb and beta-3 Integrins</PDB_Title>
      <PDB_ID>1KUZ</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1KUZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structures of the cytoplasmic tail complex from platelet integrin alpha IIb- and beta 4-subunits</PubMed_Title>
      <Author>Weljie AM</Author>
      <Journal>Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5878-83</Journal>
      <PubMed_ID>11983888</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution Structure of the Membrane Proximal Regions of alpha-IIb and beta-3 Integrins</PDB_Title>
      <PDB_ID>1KUP</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1KUP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structures of the cytoplasmic tail complex from platelet integrin alpha IIb- and beta 3-subunits</PubMed_Title>
      <Author>Weljie AM</Author>
      <Journal>Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5878-83</Journal>
      <PubMed_ID>11983888</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE</PDB_Title>
      <PDB_ID>2VDK</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta4</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO FIBRINOGEN GAMMA CHAIN PEPTIDE,LGGAKQAGDV</PDB_Title>
      <PDB_ID>2VDP</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta9</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO FIBRINOGEN GAMMA CHAIN PEPTIDE, HHLGGAKQAGDV</PDB_Title>
      <PDB_ID>2VDO</PDB_ID>
      <Resolution>2.51</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta8</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SOLUTION STRUCTURE OF THE CONSTITUTIVELY ACTIVE MUTANT OF THE INTEGRIN ALPHA IIB CYTOPLASMIC DOMAIN</PDB_Title>
      <PDB_ID>1DPQ</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1DPQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A structural basis for integrin activation by the cytoplasmic tail of the alpha IIb-subunit</PubMed_Title>
      <Author>Vinogradova O</Author>
      <Journal>Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1450-6</Journal>
      <PubMed_ID>10677482</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE</PDB_Title>
      <PDB_ID>2VDL</PDB_ID>
      <Resolution>2.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta5</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Bicelle-embedded integrin alpha(IIB) transmembrane segment</PDB_Title>
      <PDB_ID>2K1A</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2K1A</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the integrin alphaIIb transmembrane segment</PubMed_Title>
      <Author>Lau TL</Author>
      <Journal>J Biol Chem. 2008 Jun 6;283(23):16162-8</Journal>
      <PubMed_ID>18417472</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO ANTAGONIST EPTIFIBATIDE</PDB_Title>
      <PDB_ID>2VDN</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta7</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural basis for allostery in integrins and binding of ligand-mimetic therapeutics to the platelet receptor for fibrinogen</PDB_Title>
      <PDB_ID>1TYE</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1TYE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-ACETYL-D-GLUCOSAMINE</Ligand_Name>
      <PubMed_Title>Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics</PubMed_Title>
      <Author>Xiao T</Author>
      <Journal>Nature. 2004 Nov 4;432(7013):59-67</Journal>
      <PubMed_ID>15378069</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO ANTAGONIST TIROFIBAN</PDB_Title>
      <PDB_ID>2VDM</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta6</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO ANTAGONIST L-739758</PDB_Title>
      <PDB_ID>2VC2</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VC2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-(S)-[N-(3-PYRIDYLSULFONYL)AMINO]-3-[[2- CARBONYL-5-[2-(PIPERIDIN-4-YL)ETHYL]-THIENO[2,3- B]THIOPHENEYL]AMINO]-PROPIONIC ACID</Ligand_Name>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta3</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of headpiece of integrin aIIBb3 in open conformation</PDB_Title>
      <PDB_ID>3FCU</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3FCU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces</PubMed_Title>
      <Author>Zhu J</Author>
      <Journal>Mol Cell. 2008 Dec 26;32(6):849-61</Journal>
      <PubMed_ID>19111664</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR structure of the cytoplasmic domain of integrin AIIb in DPC micelles</PDB_Title>
      <PDB_ID>1S4W</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1S4W</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Membrane-mediated structural transitions at the cytoplasmic face during integrin activation</PubMed_Title>
      <Author>Vinogradova O</Author>
      <Journal>Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4094-9</Journal>
      <PubMed_ID>15024114</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SOLUTION STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE INTEGRIN ALPHA-IIB SUBUNIT</PDB_Title>
      <PDB_ID>1DPK</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1DPK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A structural basis for integrin activation by the cytoplasmic tail of the alpha IIb-subunit</PubMed_Title>
      <Author>Vinogradova O</Author>
      <Journal>Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1450-5</Journal>
      <PubMed_ID>10677482</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05414</Pathway_ID>
      <Pathway_Title>Dilated cardiomyopathy</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cardiovascular diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04151</Pathway_ID>
      <Pathway_Title>PI3K-Akt signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05206</Pathway_ID>
      <Pathway_Title>MicroRNAs in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04919</Pathway_ID>
      <Pathway_Title>Thyroid hormone signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04919</Pathway_ID>
      <Pathway_Title>Thyroid hormone signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05414</Pathway_ID>
      <Pathway_Title>Dilated cardiomyopathy</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cardiovascular diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04015</Pathway_ID>
      <Pathway_Title>Rap1 signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05222</Pathway_ID>
      <Pathway_Title>Small cell lung cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04510</Pathway_ID>
      <Pathway_Title>Focal adhesion</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04510</Pathway_ID>
      <Pathway_Title>Focal adhesion</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04810</Pathway_ID>
      <Pathway_Title>Regulation of actin cytoskeleton</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell motility</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04640</Pathway_ID>
      <Pathway_Title>Hematopoietic cell lineage</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04380</Pathway_ID>
      <Pathway_Title>Osteoclast differentiation</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Development</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04151</Pathway_ID>
      <Pathway_Title>PI3K-Akt signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04640</Pathway_ID>
      <Pathway_Title>Hematopoietic cell lineage</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05205</Pathway_ID>
      <Pathway_Title>Proteoglycans in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04611</Pathway_ID>
      <Pathway_Title>Platelet activation</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04512</Pathway_ID>
      <Pathway_Title>ECM-receptor interaction</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signaling molecules and interaction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04512</Pathway_ID>
      <Pathway_Title>ECM-receptor interaction</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signaling molecules and interaction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04512</Pathway_ID>
      <Pathway_Title>ECM-receptor interaction</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signaling molecules and interaction</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a/b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.d.ii.b.b.ba.html</SCOP_URL>
    <CATH_Class>Mainly beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1tye</CATH_URL>
  </Fold>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD00240008</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01690001</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>